BioSpace News Archive

4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company) today announced that the initial interim landmark data analysis (24 weeks) from the randomized Dose Expansion stage (N=50) of the Phase 2 PRISM clinical trial in high anti-VEGF (vascular endothelial growth factor) treatment need (6-12 anti-VEGF injections in prior 12 months) wet AMD patients will be presented at the Angiogenesis, Exudation, and Degeneration 2024 Conference being held virtually on February 3, 2024.

Centene Corporation, a leading healthcare enterprise committed to helping people live healthier lives, announced that its Chief Executive Officer, Sarah M. London, was named one of Modern Healthcare’s 100 Most Influential People of 2023.

CARsgen Therapeutics Holdings Limited announces that the U.S. Food and Drug Administration (FDA) has granted Investigational New Drug (IND) clearance for CT071.

Polaris Group (The Company, TWSE:6550), today announced that the first patient is successfully dosed in a pivotal Phase 3 trial that combines ADI-PEG 20 or placebo with traditional chemotherapy as systemic treatment in the second or third line for LMS.

Apollomics Inc. today announced the presentation of vebreltinib efficacy and safety data from the ongoing multi-cohort Phase 2 KUNPENG trial (NCT04258033) and the ongoing global multi-cohort Phase 2 SPARTA trial (NCT03175224) at the 2023 IASLC North America Conference on Lung Cancer (NACLC), that was held December 1-3, 2023, in Chicago, Illinois.

Syndax Pharmaceuticals today announced that the Company will host an in-person investor event, along with a live webcast, on Monday, December 11, 2023 , at 7:00 a.m. PT / 10:00 a.m. ET during the 65th American Society of Hematology (ASH) Annual Meeting in San Diego, California.

Philochem and Blue Earth Diagnostics Announce First Three Patients Imaged in Phase 1 Clinical Trial of 68 Ga-OncoFAP ( 68 Ga-OncoFAP-DOTAGA) for Diagnostic Imaging in Solid Tumors.

Tiziana Life Sciences Ltd. today announces that Matthew Davis, Chief Operating Officer and Chief Medical Officer will present at the Webull LIVE! with Corporate Connect: Virtual Biotech Investment Webinar on Wednesday, December 6th at 3:00 PM ET.

PerkinElmer today announced that it has acquired Covaris, a leading developer of solutions to empower life science innovations.

Catalyst Pharmaceuticals, Inc. today announced the appointment of Michael W. Kalb as its Executive Vice President and Chief Financial Officer, effective on January 1, 2024.